. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: Cancer Prev Res (Phila). 2016 Dec 5;10(1):36–44. doi: 10.1158/1940-6207.CAPR-16-0162

Table I.

Analysis of minimal erythemal dose (MED)

		Univariate analysis
Variable	Patients	Effect ratio^* (95% CI), P value
Treatment
Placebo	50 (50%)	1.00
Drug	50 (50%)	0.95 (0.91–1.00), 0.068
MC1R status
Low-risk	50 (50%)	1.00
High-risk	50 (50%)	1.00 (0.95–1.05), 0.941

Effect ratio is the ratio of post-treatment MED to pre-treatment MED.

Additional analyses of age, gender, height, weight, hair color, and eye color as covariates did not reveal any significant predictors (not shown). We did not find a significant interaction between treatment and MC1R status variables (P=0.745)